All posts by medical

Isn’t that a bit creepy? Robots with ‘human’ brains – Innovation Origins

How will robots change the world? A frequently asked and as yet unanswered question. After all, we do not have a crystal ball. What we do know is that digitalization and automation have changed the world enormously in recent decades. At Eindhoven University of Technology (TU/e) in the Netherlands, the potential of smart machines in industry and daily life is being researched each and every day. Scientists immerse themselves in technology and student teams get to work on concrete solutions to social problems. This series will tell you about the latest robots, their background, and their future. Today, the seventh episode today: social robots.

In the Social Robotics Lab at TU/e, researchers and students are taking up the challenge: They are researching the ways to teach social skills to robots. Will robots still be distinguishable from humans in the future?

We are using robots more and more often in everyday life, for instance in the workplace or for domestic tasks. Practical and repetitive tasks can be performed very well by robots, even better than humans can. But how close do you actually get to someone when you want to ask something? And during a conversation, how long do you look at someone before you look away? These are all social skills that we dont even think about, these things just happen automatically. For a robot, these things are difficult to determine, especially because they are not set facts or tasks.

Emilia Barakova and Raymond Cuijpers, the founders of the Social Robotics Lab, are working on these issues each and every day. Barakova is a senior lecturer on socially intelligent systems at the Faculty of Industrial Design and Cuijpers researches cognitive robots and human-robot interactions. We teach the robots specific skills step by step, Barakova explains. This always involves a great deal of research. So it seems that in the coming years, we will not have to worry about perfect social robots that are going to lead their own lives.

It is a world in which human psychology and robotics converge, Cuijpers notes. Social robotics is a relatively new field of research. Where many researchers now focus on the practical and technological challenges posed by robots, Cuijpers and Barakova are looking further ahead. Because the more robots go and do things, the more important their social skills will become. For example, a lot of research is being done into robots in elderly care so that people can stay in their own homes for longer. What struck us is that people feel less social pressure with a robot. When a person needs assistance in going to the toilet, the elderly often feel a bit uncomfortable. They dont feel that way with a robot, Cuijpers explains. They need an impartial robot, a buddy, a bit like a pet. In that case, particular skills for putting someone at ease are very important.

The robot needs to be able to grasp both verbal and non-verbal communication, says Barakova. Cuijpers continues: If the robot asks how things are going, a person can say that they are doing fine. But that word in itself usually doesnt say that much. You look at facial expressions and listen to the tone to see if someone really means it. According to the researcher, the robot understands more of the context in which things are being said by also looking at non-verbal communication. According to him, this is important both for humanoid robots, (robots that resemble people), and for machines such as service robots. Most robots work with people and therefore need to understand people. It is easier for robots that look like humans to communicate non-verbally, for example with facial expressions.

Over the past few years, Barakova has been researching the use of robots in therapy for children living with autism. Recognizing non-verbal communication is very difficult for these children. The robot has learned a number of non-verbal forms of communication which it can then convey to the child. For instance, the robot and a child can play the memory game together. The child flips over a card and the robot looks at the matching card that is still turned upside down. This teaches the child to follow the robots viewing direction in order to find the card, Barakova continues. Following the viewing direction is a social skill that people often use in everyday life. This kind of robot is also capable of supporting people with cognitive or visual impairments. The robot is then a sort of coach that helps you to express yourself in a certain situation.

In order to train a robot in social behavior, Cuijpers primarily focuses on the psychology of humans. There is a lot of literature on human behavior. For example, qualitative rules have been drawn up by psychologists with regard to making eye contact. The person who is listening looks at the other person almost the whole time, while the person who is talking occasionally stares into space, he says. Im trying to translate this into a model, as in qualitative rules, that the robot can apply. We can subsequently test this and refine it until we are satisfied with the robots behavior.

Apart from that, Cuijpers states that the robot makes use of a number of basic social rules, e.g. traffic rules. A graduate has done research into autonomous carts that drive through hospital corridors to pick up laundry. The robot uses navigation to know where to drive to. When doing that, it makes use of the basic rules, like always driving on the right-hand side. Things get interesting when there is an obstacle on the road, he says. In principle, the robot can then drive past on the left, provided there is no oncoming traffic. Then it has to either speed up, slow down or come to a standstill. In order to make a decision, it must also look at what the other person is doing and indicate what it intends to do. Consequently, it must be able to read and give non-verbal signals.

Ultimately, a lot of testing is required to be able to use these types of applications. The interaction between people, which is often explored in psychology, is different from the interaction between people and robots, Cuijpers explains. In addition, a model can work well with a single person in a room, but it becomes more difficult when there are several people. These are all aspects that the researchers need to take into account.

Worldwide research is being done on robots. Asia is at the forefront of this, says Barakova. After her Ph.D., she worked for a number of years in various Japanese laboratories where research is focused on social robotics. Robots are much more widely accepted there, whereas people are more skeptical in the Netherlands, she says. In order to convince people of the advantages of robots, Barakova believes that more robust applications are called for. Robots have to be able to work anytime and anywhere. When people experience what its like to work with a robot and when they see what the possibilities are, they are often more open to it, she notes. In the near future, we will be investigating new applications and looking at how we can best incorporate robots into peoples work or daily lives.

Are you curious about the other special robots at the TU/e High Tech System Center? Read the previous episodes about Experts in Robotics them here.

See more here:
Isn't that a bit creepy? Robots with 'human' brains - Innovation Origins

Scientists use gene therapy and a novel light-sensing protein to restore vision in mice – National Institutes of Health

News Release

Thursday, October 22, 2020

NIH-funded therapy will now be tested in humans.

A newly developed light-sensing protein called the MCO1 opsin restores vision in blind mice when attached to retina bipolar cells using gene therapy. The National Eye Institute, part of the National Institutes of Health, provided a Small Business Innovation Research grant to Nanoscope, LLC for development of MCO1. The company is planning a U.S. clinical trial for later this year.

Nanoscopes findings, reported today in Nature Gene Therapy, show that totally blind micemeaning they have no light perceptionregain significant retinal function and vision after treatment. Studies described in the report showed that treated mice were significantly faster in standardized visual tests, such as navigating mazes and detecting changes in motion.

Opsins are proteins that signal other cells as part of a cascade of signals essential to visual perception. In a normal eye, opsins are expressed by the rod and cone photoreceptors in the retina. When activated by light, the photoreceptors pulse and send a signal through other retinal neurons, the optic nerve, and on to neurons in the brain.

A variety of common eye diseases, including age-related macular degeneration and retinitis pigmentosa, damage the photoreceptors, impairing vision. But while the photoreceptors may no longer fully function, other retinal neurons, including a class of cells called bipolar cells, remain intact. The investigators identified a way for bipolar cells to take on some of the work of damaged photoreceptors.

The beauty of our strategy is its simplicity, said Samarendra Mohanty, Ph.D., Nanoscope founder and corresponding author of a report on the mouse study that appears today in Nature Gene Therapy. Bipolar cells are downstream from the photoreceptors, so when the MCO1 opsin gene is added to bipolar cells in a retina with nonfunctioning photoreceptors, light sensitivity is restored.

The strategy could overcome challenges plagued by other approaches to retinal regeneration, according to the researchers. Gene replacement therapy has thus far worked principally in rare diseases that leave photoreceptors intact, such as Luxurna for Leber congenital amaurosis. Bionic eyes, such as the Argus II retinal prosthesis, require invasive surgery and wearable hardware. Other opsin replacement therapies require the intensification of light in order to reach the threshold required for signal transduction. Intense light risks further damage to the retina. Nanoscopes therapy requires a one-time injection into the eye and no hardware. MCO1 is sensitive to ambient light, so no need exists for strong light to be shined into the eye. And therapy with MCO1 could treat a wider range of degenerative retinal diseases, since photoreceptor survival not required.

The researchers found no concerning safety issues in treated mice. Examination of blood and tissues found no signs of inflammation due to treatment and the therapy had no off-target effect only bipolar cells expressed the MCO1 opsin.

Under a best-case scenario, the therapy could help patients achieve 20/60 vision, according to the researchers; however, no one knows how the restored vision will compare to normal vision.

A clinical study in people will help us understand how signaling through bipolar cells affects vision quality; for example, how well treated eyes can pick out fast-moving objects., said Subrata Batabyal, Ph.D., lead author of the manuscript. The therapy will likely be limited for treatment of patients with severe retinal disease.

If this optogenetic approach using cells spared in degenerated retina can prove to be effective in vision restoration in humans, beyond light perception, it could offer a valuable alternative to the retinal prosthesis approach for people with late-stage retinitis pigmentosa, said PaekGyu Lee, Ph.D., NEIs program officer for the Small Business Innovation Research program.

This press release describes a basic research finding. Basic research increases our understanding of human behavior and biology, which is foundational to advancing new and better ways to prevent, diagnose, and treat disease. Science is an unpredictable and incremental process each research advance builds on past discoveries, often in unexpected ways. Most clinical advances would not be possible without the knowledge of fundamental basic research.

The Small Business Innovation Research (SBIR) program is a competitive awards-based funding mechanism that supports U.S.-based small businesses engaged in research and development that has the potential for commercialization. The NEI SBIR program specifically provides funding to companies developing technologies and innovations relating to blinding eye diseases, visual disorders preservation of sight, and addressing the special health problems and requirements of individuals with impaired vision.

NEI leads the federal governments research on the visual system and eye diseases. NEI supports basic and clinical science programs to develop sight-saving treatments and address special needs of people with vision loss. For more information, visit https://www.nei.nih.gov.

About the National Institutes of Health (NIH): NIH, the nations medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit https://www.nih.gov/.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

DOI is 10.1038/s41434-020-00200-2

###

Read the original post:
Scientists use gene therapy and a novel light-sensing protein to restore vision in mice - National Institutes of Health

Second Ithaca Drought in Five Years Threatens Water Supply and Local Ecosystem – Cornell University The Cornell Daily Sun

Climate change is driving the development of drought patterns in New York, threatening the agricultural sector and drying up local water sources including Ithaca.

Last month, the water supply in Six Mile Creek was at a third of its average flow rate: an alarming five cubic feet per second as opposed to its standard rate of 15 cubic feet per second. The low flow rate prompted Cornell and the City of Ithaca to issue a Level 1: Limited Water Use Advisory to encourage more water conservation on Sept. 22. The advisory was only lifted on Oct. 21.

This is the second time in less than five years that Ithaca has experienced a drought. According to the Cornell Institute for Climate Smart Solutions, the 2016 drought caused a majority of unirrigated rain-fed crops in New York to experience crop failures.

Drought is how far we are from our normal amount of rainfall relative to what the ecosystem has evolved to need, said Prof. M. Todd Walter, biological and environmental engineering.

This shift in water supply can be severely detrimental it would take only a year of continuous drought conditions in Ithaca for many species in the current ecosystem to either adapt or die off and be replaced with more drought-tolerant species.

We are very sensitive to short-term drought because our soil is shallow, and our plants have a small reservoir of water to draw from, Walter said.

Fall Creek is at half its average water level, further exacerbated by the Universitys lack of a water reservoir or other water storage methods.

Cameron Pollack / Sun File Photo

Cayuga Lake, as seen from Stewart Park, in 2017.

Another challenge we face here is this cyclical movement of people, said Harman Singh Dhodi, grad, who studies urban water systems. [Students] move in during the semester and [then leave].

The oscillating demand for water, which mirrors student residential periods, shapes the Universitys water management systems. Last semester when students were suddenly asked to leave campus there was an excess of water, but the University took no proactive measures to use the water, Dhodi said.

The University could not direct its water toward the citys needs because of the distinct systems that are employed by Ithaca and Cornell. This caused Ithacas water system to deplete while the Universitys supply sat idle, according to Dhodi.

On the other hand, Dhodi said that water recycling and reuse are not employed enough, and advocates for tackling the stigma against using chemically and biologically treated wastewater that is otherwise ejected into Cayuga Lake.

Because of water supply reducing naturally due to global warming and climate change, [time has come] to use our water more judiciously and efficiently, Dhodi said. Why is this not a common practice? Its because everyone thinks we have plenty of water, we have the Great Lakes and Finger Lakes, its a psychological thing.

The droughts in Ithaca represent a larger pattern across New York State as it increasingly experiences arid conditions due to climate change.

The biggest issue is communication and human behavior. People are struggling with the timescale of climate change, said Prof. Edwin Cowen, civil and environmental engineering, and director of the DeFrees Hydraulics lab. COVID-19 demonstrates the challenges we face with climate change. How can people worry about long-term consequences when they cant get food on the table for their kids?

Increased climate variance has major consequences on New Yorks ecosystems and the likelihood of future droughts in Ithaca.

I wouldnt be shocked before I die to hear that the Adirondacks and Catskills [are burning], Cowen said.

See original here:
Second Ithaca Drought in Five Years Threatens Water Supply and Local Ecosystem - Cornell University The Cornell Daily Sun

Proposition 24 puts power back in the hands of consumers – The Stanford Daily

The November election is fast approaching. One of the most important decisions Californian voters have will not be concerning who gets voted into office. Instead, it will be a vote on a ballot proposition concerning the future of privacy in the digital era. Proposition 24 is a monumental leap forward in securing desperately needed privacy regulations on tech and data firms that ultimately places power back in the hands of consumers and the people.

Proposition 24 is a ballot measure that will build upon the pioneering work of the California Consumer Privacy Act by giving consumers greater control over their personal data and information. The following are among the many improvements to the CCPA that are introduced by Prop. 24: the right to correct your data, personal data minimization (preventing companies from collecting large amounts of unnecessary personal information), personal right to opt-out of precise geo-location targeting and more. They are a particularly promising set of improvements for those who identify as having minority status, as Proposition 24 grants greater control over the sensitive identifying information that exists on all of us in the digital sphere.

Notably, if implemented the proposition creates a state agency. The agency would be an offspring of the California Department of Justice and would be charged with oversight of state business and department compliance with privacy laws. It does not take away authority from the legislature, which rightly should continue having the power to implement privacy legislation. Rather, it utilizes the power of the people through the ballot measure process to ensure all businesses in California remain compliant with the shifting privacy landscape. The current regulatory environment makes it difficult for businesses especially non-Big-Tech giants to understand the complex legal landscape. The new state agency will bring power to small businesses and ensure that smaller firms can compete more effectively with the Big Tech monopolies, which have teams of lawyers to interpret the evolving landscape of privacy laws.

This ballot measure will bring the greatest benefit to the children of California, who are exceptionally vulnerable to privacy violations by tech firms. The measure increases the fines for illegal use of childrens data three-fold, ensuring that tech and data platforms are upholding the highest standards of privacy and efficacy in dealing with childrens data. For a generation that has grown up in the digital age, spending most of their lives online, it is vital that Proposition 24 is passed to ensure all children are protected from exploitative practices and that they have the right to self-determination in the digital age. Children deserve it.

Big Tech platforms like Google, Facebook and Twitter effectively own a monopoly over the tech industry by engaging in freedom-destroying practices under the guise of capitalism, called surveillance capitalism. Their goal is not humanitarian in nature; rather, they seek to standardize and increase the efficiency of human behavior. They exploit our personal information and right to self-determination by placing bets on behavioral future markets bets that profit by predicting what you and I might do in the future given our past behavior on platforms. Proposition 24 is a safeguard against these exploitative practices and ultimately means greater freedom for all Californians.

Big Tech platforms now pose an existential threat to our cherished rights in the digital age. California has the chance to lead the country in Big Tech regulation and technology policy through the passage of the measure. Proposition 24 takes power away from Big Tech firms, which dominate so many aspects of our lives, and places power where it rightfully belongs: in the hands of the people and consumers.

For privacy, for children and for freedom, the Student Privacy Committee pleads to all eligible Californian voters: Vote yes on Proposition 24. It is the first step forward in what will be a long-term fight for greater privacy and power in the digital age. Lets win this fight, together.

Chaze Vinci Executive Director of the Student Privacy Committee. If you would like to contribute to the work of the committee and help advance privacy in the digital age, contact Chaze Vinci at [emailprotected].

Contact Chaze Vinci at cvinci at stanford.edu.

The Daily is committed to publishing a diversity of op-eds and letters to the editor. Wed love to hear your thoughts. Email letters to the editor to eic at stanforddaily.com and op-ed submissions to opinions at stanforddaily.com.

Follow The Daily on Facebook, Twitterand Instagram.

Continued here:
Proposition 24 puts power back in the hands of consumers - The Stanford Daily

Seasonality of the SARS 2 Coronavirus – Harvard Magazine

Many viruses are known to be seasonal, but as COVID-19 cases in late October reached a record high in the United States, even epidemiologists who have been warning for months that the pandemic will worsen with the approach of Northern hemisphere winter were surprised by the sudden upturn in casesand the accelerating pace of deaths.

The seasonality of the disease may have lulled many people into believing that their efforts at masking and social distancing were responsible for decreased cases during the summer, according to assistantprofessor of epidemiology Michael Mina, who is a leadingadvocate of the use of rapid testingas a public-health measure to suppress outbreaks and allow re-opening of schools and the economy. A better way to think about it, he said during an October 23 call with reporters, is thatWe had an opportunity to use and leverage the decreased transmission of the virus during the summer months to prepare for the fall. Now that the opportunity to deploy vast numbers of cheap tests before a fall reopening has been squandered, We are really left with impossible decisions, he said: either remaining locked down and dealing with the political and economic fallout; or staying open and reckoning with the health consequencesmeaning some people wont live as a result.

On October 25, Mina tweeted thatthe 14-day average rate of growth in COVID-19 deaths had leapt from 7 percent to 15 percent in just 3 days, meaning thatU.S. deaths were accelerating at a rapid pace.

As the reopening of society collided with seasonal factors, Mina and other epidemiologists had expected an increase in coronavirus infections and deaths. He had tweeted in early October that If we do not get this virus under control now, we are in for a perfect and terrible storm. But even experts have difficulty predicting the extent of seasonalitys impact in the months ahead,because We dont know either the magnitude or the mechanisms, says professor of epidemiology Marc Lipsitch, director of Harvards Center for Communicable Disease Dynamics.

Last spring, he and other epidemiologists estimated about a 20 percent difference in transmissibility between the seasonal trough in summer and the peak in winter, based on studies of other coronaviruses. That modest-seeming effect could nevertheless have a significant impact if the use of masks and social distancing in summer, plus a drop in viral activity, ensured thatinfected individuals transmitted the virus to just one other person on average. Conversely, an increase of 20 percent from that rate would drive anexpandingnumber of infections.

There are plenty of theories, and enough circumstantial evidence, to suggest that seasonality is driven by multiple factors, including environmental impacts on the virus and the host immune system, as well as human behavior. When temperatures drop below 65 degrees, for example, many people begin to spend more time indoors, where distancing is more difficult, and the lack of ventilation allows airborne viral particles to accumulate.

Edward Nardell, professor of environmental health and immunology and of medicine, illustrated the latter point during a June 26 talk. Much of the transmission of SARS-CoV-2 is thought be via large respiratory droplets, he said:Normally we think of them as settling down within a meter or so of the source and for good measure, weve insisted on a six-foot distance between people. While facemasks capture large respiratory droplets, and even small ones to some degree, evaporation from very small exhaled particles can allow droplet nuclei to become suspended and move with air patterns. Nardell documented the concentration of carbon dioxide (CO2) in an office with five occupants during a three-hour timespan. (Because people exhale CO2, the gas is a good surrogate for the fraction of rebreathed air in a room, and thus the risk of infection from airborne viral particles.) During the first two hours, with the window open, the level of CO2remained fairly constant. But within just 60 minutes of closing the window, the rebreathed fraction of air, and thus the risk of infection,doubled.

Several other factors could play a role in seasonal transmission:

On the other hand, Lipsitch said to reporters last week, scientists may already know the most important, actionable factors relevant to transmission of SARS-CoV-2: airflow, crowding, mask-wearing, and distance. It may not matter whether someone is in a grocery store, a fabric store, or a bar, he said. What may matter most is the number of people, the space between them, the ventilation, and the amount of vocalization.

As the holidays approach, students travel home, and temperatures drive people indoors, Lipsitch is often asked what he would recommend with respect to annual family gatherings. One neighbor asked him in particular what to do about Thanksgiving. His own gathering of 16 family members, he told her, would not be taking place this year. But people have a very real need to see their families and will have to figure out how to do that safely. One suggestion he made was to celebrate early, outdoors, with a couple of people at a time: a backyard Thanksgiving in October, or later in the yearfarther south.

The guiding principles are all the same, he continued: ventilation [by being] outdoors; small groups; staying at a distance; and masking. I dont think that big holiday gatherings make a lot of sense. So, I would recommend doing as much socializing as you can outdoors while the weather permits.

Asked why it was important to keep gatherings small, Lipsitch explained that the risk to each person in a group goes up in proportion to the size of the gathering. If theres a half percent chance that each person is infectious, then in a group of five, theres approximately a two-and-a-half percent chance that at least one person is infectious. The probability rises as the numbers increase, and at the same time, the chance that the number of people exposed goes up. Roughly speaking,doubling the size of a group increases the risk of transmission by a factor of fourandtripling(from two people to six, for example)raises risk ninefold, because you have three times as many potentially infectious people and three times as many recipients. Furthermore, Lipsitch added, Risk always rises with the prevalence of infection in the places people are coming from.

Knowing all this can help individuals, families, and local communities mitigate their risk, but What we dont have right now is a comprehensive answer for how to get from high levels of community transmission back down to very low levels without lockdown or intense social-distancing interventions, Lipsitch continued. That is the task that lies ahead for [epidemiologists] and I think testing would be at the center of that, but on a much, much larger scale than we have. Already, he pointed out, places that have the resources (including some universities, companies, and the NBA) have successfully controlled transmission with very extensive testing together with isolation of infected individuals. The question, he said, is whether the amount of testing that the United States can realistically create overlaps with the amount that would be effective at scale.

Mina, at the forefront of efforts to develop faster, cheaper testing, has met with officials at U.S. regulatory agencies, and says that several significant bureaucratic obstacles to rapid testing have been removed. Still missing, however, is a coordinated federal response, including a commitment to spend the $20 billion that he estimates would be needed to deploy a national testing strategy by Januarysmall change compared to the$16 trillion in estimated economic damagesattributable to the pandemic, includingthe loss of 2.5 million years of potential lifeso far in the United States alone. Were all hoping that a vaccine will create herd immunity, he continued, but there wont be enough vaccine for everyone until late spring or early summer.

At this point for Mina, it is dj vu, as once-avoidable increases in hospitalizations threaten to overwhelm the capacity of health-care systems, just as they did in April. I dont want to see everything close down again, he tweeted recently. I dont want to see people spending their last days alone.

Read the original here:
Seasonality of the SARS 2 Coronavirus - Harvard Magazine

Bryant establishes Center for Health and Behavioral Sciences with $200000 Roddy Foundation Grant – Bryant University

Bryant Provost and Chief Academic OfficerGlenn Sulmasy, JD, LL.M,and College of Arts and Sciences InterimDean Wendy Samter, Ph.D., announce the establishment of the Center for Health and Behavioral Sciences (CHBS), which is supported by a $200,000 grant from the Fred M. Roddy Foundation, a non-profit organization that supports the fields of medicine, health care, and education. Kirsten Hokeness, Ph.D., Professor and Chair of the Science department, was appointed by Sulmasy as Director of the Center.Joseph Trunzo, Ph.D., Professor and Chair of the Psychology department, will serve as Deputy Director.

Building on our historic strengths, we are developing strategies for innovation and future growth to position our faculty and students to make significant contributions in the areas of the healthand behavioral sciences.

A multi-disciplinary approach to improving health and well-being

The mission of the CHBS is to educate and train the next generation of leaders who are dedicated to improving the health and well-being of others.The challenges of the ongoing global pandemic have highlighted the critical need for multi-disciplinary approaches to identifying and solving problems in this sector.The Center will leverage the strength of Bryants business core to become a premiere choice for students pursuing a career in health sciences, health care, or behavioral sciences.

The truly innovative and holistic approach to research and health care is what attracted us to this initiative at Bryant University."

We are grateful for the generosity of the Fred M. Roddy Foundation in providing critical funding for this important initiative that will support research and education in these interconnected disciplines, says Bryant Provost and Chief Executive Officer Glenn Sulmasy, JD, LL.M. Building on our historic strengths, we are developing strategies for innovation and future growth to position our faculty and students to make significant contributions in the areas of the health and behavioral sciences.

The truly innovative and holistic approach to research and health care is what attracted us to this initiative at Bryant University. We are also pleased to support a generation of students who will be able to work across disciplines to address complex global challenges, said Elizabeth McIntyre, President of the Fred M. Roddy Foundation. The Foundations essential mission is to support organizations carrying on research, educational or operational efforts for the cure or alleviation of afflictions of body or mind, or for general educational or charitable purposes.

"Bryant is removing traditional intellectual, physical, and geographic boundaries to enable innovation and collaboration that will prepare leaders and practitioners to solve some of the most difficult problems we face today and in the future.

We recognize that the world is not divided by academic disciplines, adds Samter. Through initiatives such as the Center for Health and Behavioral Sciences, Bryant is removing traditional intellectual, physical, and geographic boundaries to enable innovation and collaboration that will prepare leaders and practitioners to solve some of the most difficult problems we face today and in the future.

Enhancing high-quality scientific research

In addition to providing needed funding to help establish the CHBS, the Fred M. Roddy Foundation grant is funding lab equipment that will enable high-quality research. This includes a Mass Spectrometer used for the study of small molecules as part of the antimicrobial discovery program; a Behavioral Assay set-up (an environment to test stimulus response) to support neuroscience and addiction research; Dissecting Microscopes; a Superspeed Centrifuge to process different types of biological materials; and a Psychophysiology iMotion Computer package that measures physiological responses to stimuli.

With this equipment, faculty, including the two newly hired tenure track faculty in the science and psychology departments and students will be better equipped to produce high-quality research and secure additional funding through various granting agencies. Undergraduate students will have the unique opportunity to work one-on-one with faculty on projects linked to health and healthcare, preparing them to be competitive when seeking employment or to succeed in gaining acceptance to prestigious graduate programs in the health and behavioral sciences.

A holistic view

Our goal is to ensure that students understand the scientific foundations of human health and disease along with the core concepts in their chosen field of study, while gaining a holistic view of the healthcare industry, human behavior, and mental processes, says Hokeness describing her vision for the Center. Student researchers and graduates will emerge with a skillset required of practitioners, employees, and scholars who will ultimately become leaders and change agents who value collaboration, enriching the lives of their community.

Whether its a practitioner on the front lines treating patients, a researcher hunting for vaccine candidates, a psychologist addressing the impact of the virus on the wellness of the population, a communication expert working to deliver messaging to the public, an economist examining the effects of the pandemic on the global economy, or a manager in a healthcare facility understanding patient needs, The education and training that happens at the CHBS will enable students, scholars, leaders, and practitioners to successfully navigate the interconnected nature of human health and wellness, adds Trunzo.

Building on Bryants unique integration of the arts and sciences with business, academic program development in the area of health and behavioral sciences will develop highly skilled employees for a sector that positioned for future growth.

For 158 years, Bryant University has been at the forefront of delivering an exceptional education that anticipates the future and prepares students to be innovative leaders of character in a changing world. Located on a contemporary campus in Smithfield, R.I., Bryant enrolls approximately 3,800 undergraduate students from 38 states and 49 countries. Bryantis recognized as a leader in international education and regularly receives top rankings fromU.S. News and World Report, Money, Bloomberg Businessweek, Wall Street Journal, College Factual,andBarron's.Visithttps://www.bryant.edu/.

See more here:
Bryant establishes Center for Health and Behavioral Sciences with $200000 Roddy Foundation Grant - Bryant University

What’s behind Virginia’s increasing pedestrian death toll and how to reverse the trend – Virginia Mercury

On Thursday evening, friends and family were at the intersection of Jahnke and German School roads on Richmonds Southside to mourn the loss of 16-year-old Aajah Rosemond, who was killed by a driver while walking to the store.

According to police, a collision with a GMC Yukon sent a roughly 6,000 pound Nissan Titan spiraling up and onto the sidewalk, fatally striking the teenager. The evening news tells such tales with disturbing regularity, a product of Virginias rapidly rising pedestrian death rate. However, whats behind the spike and how to fix it are questions without simple answers.

Over the past half century, Virginia and the rest of the country have generally enjoyed a steady decline in traffic deaths. While fatalities have reached record lows for drivers, starting 10 years ago, however, that trend began to reverse for people outside of a vehicle. During the 10-year period from 2009 to 2018, the number of pedestrian fatalities increased by 53 percent (from 4,109 deaths in 2009 to 6,283 deaths in 2018), stated a recent report from the Governors Highway Safety Association. By comparison, the combined number of all other traffic deaths increased by 2 percent.

According to Mark Cole, a highway safety engineer with the Virginia Department of Transportation, pedestrian deaths truly began to shoot up in the state four years ago. Prior to 2016 Virginia was seeing about 80-100 pedestrian deaths per year. Then in 2016 we saw a big jump to over 120, he said. In 2018, there were 123 pedestrian fatalities, an increase of nearly 8 percent from the year before, according to the DMV.

Last year, 126 pedestrians and 13 bicyclists were killed on Virginias roads, the nonprofit Drive Smart Virginia reported. Nationwide, the number of people killed while walking hit a 30-year high and roads have only gotten more dangerous as some driving during the pandemic took empty streets as a chance to speed. Although some initially blamed the proliferation of smartphones, the past decade of data has shown the roots of the rising fatalities run far deeper.

One of the most obvious answers behind the jump in pedestrian deaths are the types of vehicles hitting people. It is hard to overemphasize just how suddenly and completely [SUV] crossovers have come to dominate the auto market in recent years, wrote Angie Schmitt, a planning consultant with 3MPH, in her recent book: Right of Way: Race, Class, and the Silent Epidemic of Pedestrian Deaths in America. When the economy was still recovering from a recession, in 2012, 83 percent of vehicles sold in the United States were sedans.

As wages rose and gas prices dropped, however, Americans increasingly began purchasing SUVs and heavy-duty trucks. Now almost no sedans are being sold, and the whole market is trucks and SUVs, she said in an interview. That means cars are getting bigger, taller and deadlier.

From his work mapping and analyzing crash data with VDOT, Cole agrees with the diagnosis: The vehicle fleet has been changing over time with SUVs and trucks becoming the greater proportion of the fleet thats on the road. Weve seen an increased number of those types of vehicles involved in crashes too. SUVs and pickups which have a higher center of gravity and higher weight result in more serious crashes.

When drivers in a sedan run into someone, that person is more likely to fly up onto the hood, an occurrence with a far higher survival rate than when someone is run over. With many SUV and truck grills now reaching as high as five feet, its nearly impossible for pedestrians not to be pushed under the vehicle. The data bear this out: One hundred percent of pedestrians in SUV collisions at speeds of 40 mph or greater died, versus 54 percent who were struck by cars.

Melicent Miller, a project manager with the state Department of Healths Virginia Walkability Action Institute, acknowledges the increased danger posed by this bigger fleet: There are some really monstrous vehicles on the streets. The odds of someone surviving contact with an SUV or a truck is much lower than when someone gets hit by a sedan.

Who pedestrians are and where theyre walking are also driving pedestrian fatalities to record highs. According to the Department of Motor Vehicles the number of individuals 65 and older killed while walking is up 95 percent over 2018 alone. Seniors have always made up one of the highest risk groups to be run over by drivers, and as the Baby Boomer generation ages, the number of those most vulnerable has multiplied.

The other factor influencing the rising pedestrian death rate is the displacement of the urban poor to the suburbs. As wealthier Whites return to city centers, Black and brown communities with lower rates of vehicle ownership are being pushed into suburban sprawl often characterized by 45 mile-per-hour speed limits, lack of sidewalks and eight-lane arterial roads.

Between 2010 and 2015, about half the growth in poverty took place in U.S. suburbs, according to the Institute for Research on Poverty at the University of WisconsinMadison, wrote Schmitt. In the United States today, more than three million more people are living in poverty in suburbs than in cities. These places and their streets, almost without exception, were not designed to accommodate people walking or relying on transit.

Americas changing vehicle fleet and shifting demographics arent responsible for the entirety of the tragic trend. Its not always easy to put your finger on what causes a crash because they reflect a lot of structural issues like land use and how a road is designed but they also bring in human behavior, Cole said. The majority of crashes weve seen involve human error.

DOTs and traffic safety campaigns often note that 94 percent of all crashes are due to human error; however, a growing coterie of city planners and urbanists are increasingly pushing back on that claim as an out for engineers to place the blame on victims of traffic collisions rather than fixing the infrastructure and design failures that cause crashes to be so deadly.

In a recent interview, Leah Shahum director of the Vision Zero Network, which is pushing to eliminate traffic fatalities said, We need to debunk the 94 percent myth because it detracts focus from the actual risk factors that are most deadly, such as poorly designed roads and dangerously high speed limits. This myth keeps communities from implementing effective policy and design solutions, which is literally killing people, especially our most vulnerable road users, including children, seniors, people with vision impairments and those walking and biking.

When explaining the growing disparities in death rates, Schmitt points to the different attention paid to making roads safe for drivers versus ensuring that people on foot can safely get where they need to go. If youre on a highway you can count on everything you need to be safe like guardrails and good lighting to be there. On our local and arterial roads a lot of the things needed to keep pedestrians safe like guard rails and curb ramps are missing.

The engagement of public health officials has helped to strengthen this approach to the problem. One of the central tenets of Vision Zero is that humans are fallible and are going to make mistakes, but we can use that information to plan for human error, said Sarah Shaughnessy, the built environment & health specialist for the Richmond City Health District. We are smart enough that we should be able to put policies and infrastructure in place to account for that.

The skyrocketing pedestrian death rate over the last four years doesnt mean Virginia officials have been sitting on their hands. There are certain ways VDOT impacts this trend like our construction and maintenance programs, and there are certain ways we dont, said John Bolecek, VDOTs bicycle and pedestrian program manager. Every way in which we interact with this issue something has changed to improve it.

A new LED lighting policy has made it cheaper to keep streets well-lit a critical enhancement since 75 percent of all pedestrian deaths occur at night. A crash-mapping project begun several years ago has also borne fruit: We learned that the majority of deaths almost always occur when a pedestrian is crossing the road, but we dont do a good job as a state, as VDOT, and as a society in providing safe crossing infrastructure for pedestrians, Cole said.

Although Virginia hasnt fully embraced Vision Zero and its goal of zero traffic fatalities as the guiding principle of its transportation planning, VDOTs most recent Strategic Highway Safety Plan Arrive Alive comes close. The two year old Pedestrian Safety Action Plan is another VDOT tool meant to guide the commonwealths cities and counties to invest more in pedestrian safety.

When localities take pedestrian deaths seriously and apply for VDOT funding to fix bad infrastructure, Bolecek has seen dramatic results: In Northern Virginia alone over the past five years theyve built out over 200 miles of bike lanes, often via road diets which have also turned center lanes into pedestrian refuges. Thats added a lot of crosswalks and moved bus stops to better locations.

Recent pushes to lower speed limits and implement handsfree bans may help, but lacking infrastructure is such a localized problem that Schmitt advises communities to conduct pedestrian safety audits to identify and address unsafe streets. Shaughnessys office often helps Richmond residents invite key stakeholders like city council members, police officers and public works officials to walk with residents and then packages that information for grants to fix the problems found.

With so much of the problem beyond the power of local and even state governments, Schmitt hopes that a new presidential administration next year could begin to tackle the epidemic of pedestrian deaths at the federal level too by dedicating more dollars to pedestrian safety and by introducing stricter vehicle safety guidelines.

Pedestrian detection and automatic braking have reduced insurance claims for pedestrian crashes by 35 percent, but the National Highway Traffic Safety Administration currently doesnt require car companies to install those technologies, which limits how effective and widespread those are, Schmitt said. The U.S. government regulates vehicles for all kinds of safety issues like air bags and auto-lock brakes, but none of those things protect folks outside of the vehicle; they only protect drivers.

CORRECTION: Mark Cole works for the Virginia Department of Transportation. This story has been update to reflect that correction.

Go here to read the rest:
What's behind Virginia's increasing pedestrian death toll and how to reverse the trend - Virginia Mercury

Research finds a problem with concept of herd immunity in COVID-19 – News-Medical.Net

A recent study published on the preprint server medRxiv* in October 2020 suggests that arguments in favor of herd immunity are weakened by the fact that the steep increase in the number of COVID-19 deaths as a result of being exposed to the virus many times instead of once or a few times is not taken.

While most have mild COVID-19, a severe disease associated with diffuse pneumonia may require hospitalization. Many in this group will eventually require intensive care, with oxygen supplementation and mechanical ventilation.

In a sizable minority of cases, death supervenes due to multi-organ failure. The survivors in this group may experience permanent disabling symptoms.

Lockdown strategies were meant to buy time for productive and preparatory measures by slowing the pace of viral transmission. Vaccines are meant to elicit neutralizing immunity to the virus and prevent endemicity. Since this is an RNA virus, it is bound to undergo numerous mutations, which will make it more difficult to eradicate it in endemic form.

Another school of thought holds that herd immunity is the best way to handle the pandemic. Without any interventions, the population will develop immunity naturally, while the economy will remain stable, so goes the argument. However, the World Health Organization (WHO) chief has termed this an unethical idea.

The researchers in the current study say that herd immunity appears appealing only because it is backed by simplistic simulations that ignore real-time health care challenges. Moreover, durable immunity to SARS-CoV-2 has not yet been proved.

Again, this model does not consider the higher death rates bound to occur with an overburdened healthcare system as infections surge. And finally, it ignores the long-term disabling effects of this illness, the medical and the social costs of caring for such individuals.

The uncontrolled viral spread will cause endemic COVID-19. Novel variants may emerge that are more destructive to lung tissue. Even worse, multiple exposures may lead to a higher viral load, and therefore a more significant proportion of severe disease.

Repeated exposures could also trigger antibody-dependent enhancement (ADE) of disease severity. This is one area where wearing face masks in public all the time could make a big difference in the load placed on hospitals and HCWs, by preventing severe infections.

There are many distinct variants of the virus in circulation at the current time. These variants do show different degrees of infectivity and pathogenicity. It is unclear whether these can exist simultaneously in one patient and how they interact, if so.

Since current estimates of mortality depend on information from the early part of the pandemic, they are likely to be inaccurate since, at this time, individuals were unlikely to have repeated contacts with infected persons. One exception was HCWs, since their daily and repeated contacts with many potentially infected people rendered them capable of super-infections.

The present study aims to understand how mortality is related to the presence of multiple variants of SARS-CoV-2 acquired through multiple exposures. This model also examines how measures intended to reduce contact with infected people affect super-infections and mortality. It uses a model adapted from the free tool CovidSIM.

The researchers assumed disease stages of latent (3.7 days), prodromal (1 day), fully contagious (7 days), and late infectious (7 days), and also assumed a doubling of infectivity in the fully contagious stage compared to the first two. They found that multiple infections had a ~64% risk of causing severe symptoms and 4% mortality compared to 58% and 3%, respectively, for single infections.

Multiple infections caused more symptomatic infections, therefore more isolation, resulting in less spread and a smaller peak. But while the total number of multiple infections is somewhat reduced, especially during the epidemic's peak, the number of deaths increases.

However, seasonal infections affect this relationship, with a higher narrower peak resulting if it overlaps with the beginning of the flu season. In this case, more multi infections, and significantly more deaths, will occur than expected.

Symptom severity is measured by the number of infected individuals who come to medical attention and enter isolation, with a direct relationship between the two parameters. Higher isolation of symptomatic multi infections reduces total infection numbers somewhat, reducing the epidemic's peak and of multi infections.

The total mortality rises, however, due to the increased number of deaths caused by multi infections.

Again, multi infections reduce the overall case number but push up the number of deaths in proportion to the case fatality rate of multi infections. Again, this is aggravated by seasonality, with a higher epidemic peak, more multi infections, and more deaths if the peak comes at the beginning of the flu season.

Multi infections may be caught by one or consecutive exposures. If the latter, the effects will be delayed, and in this period, the spread is limited, while recovery may occur rather than death. Thus, this subset of infected individuals does not significantly increase the total number of multi infections.

However, the higher the risk of multi infection spread, the higher is the epidemic peak, and the greater the case fatality.

Prior infection with one strain of SARS-CoV-2 may confer partial immunity to multi infections, depending on the contagious person's stage of infection. Susceptibility is significantly less, and therefore the risk of multi infections if the susceptible person is in the late infectious phase.

While variations in susceptibility do not affect the epidemic peak, they do affect the multi infection case number. Around the peak, multi infection by exposure to two or more single infections is more likely than that due to exposure to one multi infection.

The researchers also found that reducing inter-individual contacts over a range of scenarios ranging from a second lockdown to no intervention would result in a delayed but not smaller epidemic peak in a non-seasonal scenario. Case isolation reduces the peak. In both cases, multi infections and deaths are unaffected.

With seasonal changes, fewer contacts can delay the epidemic peak to coincide with that of the flu season, increasing the peak height. The narrow, sharp peak limits the multi infection case number slightly, and the number of deaths is also somewhat lower.

A second lockdown, properly timed, can reduce the number of infections occurring after the relaxation of the first, if the epidemic peaks while the reproduction number is declining. The earlier such a lockdown is put into force, the more it overlaps the pandemic's early peak, and the greater is the delay in the eventual peak. This will also result in a broader but flatter peak.

The number of cases and deaths can be still further reduced by extending an early lockdown. If too late, however, the lockdown will be ineffective as cases are already declining.

The researchers point out, "Multiple infectious contacts and longer (average) exposure to the virus is initially restricted to certain risk groups, but will become common during the pandemic peak."

Different variants of SARS-CoV-2 may be acquired at different points by exposure to different infectious individuals. Viral diversity will also only increase during a pandemic.

Herd immunity becomes a less attractive concept given the higher viral load and multi infection risk as the pandemic progresses, coupled with more significant morbidity and mortality. Herd immunity becomes a less attractive concept versus a properly timed second lockdown. The results may vary with the duration of immunity and human behavior. For instance, some individuals may choose to avoid most forms of contact with others. The model parameters can be tweaked for several such differences.

The researchers also point out, "Notably, multi infections are not the only danger when aiming for herd immunity. An uncontrolled (or hardly controlled) pandemic inevitably renders the virus endemic."

If so, not only will it become difficult to get rid of the virus, but it could find reservoir hosts in pet animals, escaping control measures. As viral diversity increases, so might its virulence, requiring the vaccines to be adapted each year. Multiple vaccination rounds will then be required to eradicate the virus, resulting in ADE in some individuals.

The study concludes, "Increased morbidity and mortality due to multi infections is an important but overseen risk, particularly in the context of herd immunity. Evidence-based research on multi infections is necessary."

medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Read more:
Research finds a problem with concept of herd immunity in COVID-19 - News-Medical.Net

Video: COVID-19 Why it Matters: Part 12, Why huge COVID-19 spikes in Wisconsin? – UWGB

This video series features UW-Green Bays Immunologist Brian Merkel on COVID-19 and Why it Matters. This series empowers viewers with knowledge to help them navigate through the pandemic. Merkel has a Ph.D. in Microbiology & Immunology from the Medical College of Virginia. He is an associate professor in UW-Green Bays Human Biology & Biology programs and has an appointment at the Medical College of Wisconsin Department of Microbiology and Immunology. He will be responding to a number of questions related to COVID-19 and try to get behind the why its important to be educated in your decision-making as we navigate the pandemic together.

Video Transcript COVID-19 Why it Matters, Part 12: Why HUGE COVID-19 spikes in Wisconsin?

Hello, Brian Merkel, Microbiology and Immunology UW-Green Bay and we are here today to talk about why COVID-19 matters to you.

Specifically, we want to address the current spike that were having in COVID-19 in Wisconsin. I think one of the best examples of why we should be so concerned about the spikes that were currently dealing with in Wisconsin, has to do with the reality that we just opened up a field hospital in Milwaukee.

Now thats something as an educator at UW-Green Bay, that I used to talk about just in history books with the pandemic problem of 1918. Never in my life would I ever thought for a minute that we would be doing something like that now.

So, here we are. We have this terrible spike in Wisconsin now. In terms of explanations, it has to do with large gatherings and people not following the prescribed safeguards. The challenge is compliance and so we strongly encourage people to realize and theres empowerment to this because the more each of us does our part to comply with the prescribed safeguards, the better off were going to be, and themore likely were going to get a good handle on this virus.

We strongly encourage you to wear masks, wash your hands, and keep your distance, and avoid large gatherings and please stay at home when youre sick.

COVID-19 Why it Matters Video Series:

Introduction with Brian Merkel https://youtu.be/M-yYPSPk30Q

Part 1: What are viruses and where did this one come from https://youtu.be/DYbiIv8ICgs

Part 2: Two main types of viruses https://youtu.be/O-OVk3rx96s Part 3: Why is this virus serious? https://youtu.be/EDFyNN8i5G4

Part 4: Why wash hands/wear mask? https://youtu.be/FlcAvlt876Y

Part 5: Im young! Why should I care? https://youtu.be/TDrEV_beY1U

Part 6: Can pandemics be stopped before they start? https://youtu.be/lgWnJZNYbFI

Part 7: Pandemic is not local, why wear a mask? https://youtu.be/IG3Sl3q-xH8

Part 8: Why does everyone need a flu shot this year? https://youtu.be/DGpBFj0fJkA

Part 9: What is the science behind a vaccine? https://youtu.be/eQ3FclkYaQo

Part 10: Where can I find accurate information? https://youtu.be/pLMlU5Xnkgo

Part 11: What type of mask should I wear? https://youtu.be/gCFHxQvkVYE

Part 12: Why HUGE COVID-19 spikes in Wisconsin? https://youtu.be/OuqmXvrDApY

Read more from the original source:
Video: COVID-19 Why it Matters: Part 12, Why huge COVID-19 spikes in Wisconsin? - UWGB

GentiBio Expands Leadership Team and Partnership with MIGAL to Help Advance Development of Engineered Regulatory T Cell Therapies – BioSpace

BOSTON, Oct. 28, 2020 /PRNewswire/ --GentiBio, Inc., an emerging biotherapeutics company developing engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases, announced today the appointments of Catherine Thut as Chief Business Officer and Thomas Wickham as Chief Scientific Officer. In these roles, Thut will be responsible for leading the company's corporate development, strategy and financing, and Wickham will drive the company's research and development activities to advance the company's scientific platform and shape research strategy. Additionally, GentiBio expanded its existing partnership with MIGAL Galilee Research Institute to further leverage the institute's expertise in synthetic immunology.

"We are excited to welcome Cathy and Tom to our team as both come at a pivotal time for the company as we advance the development of our Regulatory T cell-based therapies," said Adel Nada, Co-founder, President and CEO of GentiBio. "Catherine brings to GentiBio extensive experience and a proven track record in business development and fundraising in the biopharmaceutical space, while Tom's deep expertise in immunology and a diverse spectrum of drug and engineered cell therapy platforms will be invaluable to the company as we further the progress of our research programs and pursue moving our therapies into the clinic. Adding their leadership to GentiBio will be critical in helping us achieve our business and scientific goals."

Catherine Thut, Ph.D., MBAThut brings vast biopharmaceutical industry experience to the GentiBio team. Cathy most recently served as CEO of Makana Therapeutics, a preclinical stage company focused in alleviating organ shortage crisis through xenotransplantation, where she led the merger of Makana with Recombinetics. Prior to Makana, Cathy was Executive Director in the Business Development and Licensing group at Novartis Institutes for BioMedical Research (NIBR), where she worked across multiple therapeutic areas and was responsible for negotiating a number of immuno-oncology partnerships. Cathy also worked at Merck Research Laboratories as Therapeutics Area group leader for Ophthalmology Research. She pursued her graduate and postdoctoral training at U.C. Berkeley and Stanford University Medical School, respectively, and received her MBA from MIT's Sloan School of Management.

"I'm excited to work with the GentiBio team to bring my corporate development and business strategy experience to the company as we work to determine how our unique therapeutic modality can directly address the underlying cause of autoimmune, alloimmune, auto inflammatory and allergic diseases," said Thut. "GentiBio's platform has the potential to realize the promise of EngTregs cell therapy products in the treatment of serious diseases, and I'm eager to help make this a reality for patients."

Tom Wickham, Ph.D.Tom brings over 25 years of experience in advancing drug platforms in a variety of therapeutic areas from discovery through clinical trials. Most recently, Tom served as Senior Vice President of Research and Development at Rubius Therapeutics, where he pioneered synthetic biology approaches using genetically engineered red cells for autoimmunity, immuno-oncology, and rare disease applications, building a full discovery and preclinical organization leading to multiple product programs and two regulatory filings. Prior to Rubius, he held senior roles at numerous leading biopharmaceutical companies, including as Vice President of R&D at Merrimack Pharmaceuticals, Senior Director of Preclinical Pharmacology at EMD Lexigen (now Merck-Serono), and at GenVec, Inc. Tom holds a B.S. in chemical/biomedical engineering from Carnegie Mellon University, a Ph.D. in biochemical engineering from Cornell University, and pursued his postdoctoral training at the Scripps Research Institute in the Department of Immunology.

"Understanding the limitations in existing regulatory T cell-based therapeutics, I'm motivated by the innovative approach GentiBio is taking to successfully restore immune tolerance in the body," said Wickham. "I look forward to bringing my expertise with advancing drug platforms to GentiBio as I truly believe Regulatory T cell biology coupled with smart and fit-for-purpose receptor engineering has the potential to treat and cure many patients living with serious autoimmune and inflammatory diseases."

Expanded MIGAL Galilee Research Institute PartnershipIn addition to the new executive hires, GentiBio has expanded its partnership with MIGAL-Galilee Research Institute through the exclusive licensing of its unique immune evasive technology that can potentially enable durable engraftment of allogeneic cells, including EngTregs. This proprietary technology has been conceptualized and achieved building on the long standing and pioneering insights of Prof. Gidi Gross, Head, and Dr. Hadas Weinstein-Marom, Senior Scientist, Immunology Laboratory, MIGAL and Scientific Co-Founders and Scientific Advisory Board members of GentiBio.

"Enabling durable cell therapy engraftment in immune competent patients will advance the reach of EngTregs and cell therapy platforms, positioning GentiBio to become a leader in allogeneic cell therapy," said Nada. "We are thrilled to continue partnering with a premier research organization like MIGAL to advance novel and potent engineered cell therapies with the potential to treat and cure serious autoimmune and inflammatory diseases."

"The immune evasive technology is a product of many years of synthetic immunology tinkering and engineering. We are delighted to see this technology further developed and advanced by GentiBio to make it available for the many patients who can benefit from it," said Prof. Gross.

About GentiBio, Inc.GentiBio, Inc., is an early stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complimentary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T cell therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or malfunctioning of the immune system. To learn more visit https://www.gentibio.com/

About MIGAL Galilee Research InstituteMIGAL Galilee Research Institute Ltd is a regional R&D center of the Israeli Science and Technology Ministry owned by the Galilee Development Company ltd. An internationally-recognized multi-disciplinary applied research institute, MIGAL specializes in biotechnology and computer sciences, plant science, precision agriculture and environmental sciences, and food, nutrition and health. Recognized as a powerhouse of applied research, for forty years MIGAL has cooperated closely with industry leaders, innovative startups, and technological accelerators. MIGALs' employees include 90 PhDs and 190 researchers distributed across 44 research groups, operating as an innovative research ecosystem that encourages collaboration across scientific, industrial, agricultural, academic and technological specialties.

View original content to download multimedia:http://www.prnewswire.com/news-releases/gentibio-expands-leadership-team-and-partnership-with-migal-to-help-advance-development-of-engineered-regulatory-t-cell-therapies-301161205.html

SOURCE GentiBio, Inc.

Continue reading here:
GentiBio Expands Leadership Team and Partnership with MIGAL to Help Advance Development of Engineered Regulatory T Cell Therapies - BioSpace